Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Andemariam, Biree
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises	Completed	3	243	Europe, US, RoW	Inclacumab, Placebo	Pfizer	Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis	06/24	06/24
NCT02306993: Sickle Cell Hemoglobinopathies and Bone Health	Active, not recruiting	N/A	45	US	Healthy volunteers without SCT, Healthy volunteers with SCT, Volunteers with SCD	UConn Health	Sickle Cell Disease, Sickle Cell Trait	12/25	12/25
NCT06743113: Hypoxic Red Blood Cells in Sickle Cell Anemia	Not yet recruiting	N/A	48	US	Hemanext ONE System, Conventional RBCs	Hemanext, Emory University, University of Connecticut, University of Pittsburgh Medical Center, Johns Hopkins All Children's Hospital, Johns Hopkins University	Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)	02/28	06/28
PROSPECT, NCT04930445: Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD	Terminated	N/A	262	US	Oxbryta® (voxelotor) 500mg Tablets, Voxelotor, Oxbryta®	Pfizer, Pfizer	Sickle Cell Disease	10/24	10/24
Jones, Sasia
PROSPECT, NCT04930445: Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD	Terminated	N/A	262	US	Oxbryta® (voxelotor) 500mg Tablets, Voxelotor, Oxbryta®	Pfizer, Pfizer	Sickle Cell Disease	10/24	10/24